The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease

被引:4
|
作者
Jirapinyo, Pichamol [1 ,2 ,5 ]
Thompson, Christopher C. [1 ,2 ]
Garcia-Tsao, Guadalupe [3 ,4 ]
Zucker, Stephen D. [1 ,2 ]
Ryou, Marvin [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Yale Sch Med, Sect Digest Dis, New Haven, CT USA
[4] VA CT Healthcare Syst, Sect Digest Dis, West Haven, CT USA
[5] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, 75 Francis St, Boston, MA 02115 USA
关键词
LIFE-STYLE; CIRRHOSIS; FIBROSIS; OBESITY;
D O I
10.1055/a-2146-8857
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The goals of therapy for patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease include weight loss and reduction of the portosystemic pressure gradient (PPG) to decrease the risk of hepatic decompensation. Endoscopic gastric plication (EGP) is an effective endoscopic weight loss procedure. This study aimed to assess the effect of EGP on PPG. Methods In this prospective pilot study, patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease underwent endoscopic ultrasoundguided PPGmeasurement prior to and at 6months following EGP. Primary outcomes were the change in PPG and proportion of patients experiencing . 20% reduction in PPG at 6 months. Secondary outcomes included percent total weight loss (TWL) and changes in noninvasive tests of fibrosis. Results 20 patients were included. Baseline median body mass index and liver stiffness measurement were 40.2 kg/ m2 (range 30.1.56.7) and 14.7 kPa (range 8.2.36), respectively. At 6 months, median PPG decreased from 5.4mmHg (range 0.7.19.6) to 1.8mmHg (range 0.4.17.6) (P = 0.002), with 79% (11/14) experiencing . 20% reduction. Patients experienced 12.5% (6.5%.26.1%) TWL (P < 0.001) at 6 months, with 89% (17/19) achieving . 7% and 68% (13/19) achieving . 10% TWL. There were significant improvements in noninvasive tests of fibrosis. Conclusion EGP appeared to be effective at reducing PPG in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. © 2022 Georg Thieme Verlag. All rights reserved.
引用
收藏
页码:125 / 130
页数:6
相关论文
共 50 条
  • [1] Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria
    Elhence, Anshuman
    Anand, Abhinav
    Biswas, Sagnik
    Vaishnav, Manas
    Yadav, Rajni
    Das, Prasenjit
    Panwar, Rajesh
    Agarwal, Sandeep
    Gamanagatti, Shivanand
    Kumar, Ramesh
    Shalimar
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (03) : 1016 - 1025
  • [2] Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease
    Zhou, Yu-Jie
    Gao, Feng
    Liu, Wen-Yue
    Wong, Grace Lai-Hung
    Mahadeva, Sanjiv
    Mustapha, Nik Raihan Nik
    Wang, Xiao-Dong
    Chan, Wah-Kheong
    Wong, Vincent Wai-Sun
    Zheng, Ming-Hua
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (04) : 470 - 480
  • [3] Nonalcoholic Fatty Liver Disease
    Isaacs, Scott
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (01) : 149 - 164
  • [4] Nonalcoholic fatty liver disease
    Erickson, Sandra K.
    JOURNAL OF LIPID RESEARCH, 2009, 50 : S412 - S416
  • [5] Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria
    Anshuman Elhence
    Abhinav Anand
    Sagnik Biswas
    Manas Vaishnav
    Rajni Yadav
    Prasenjit Das
    Rajesh Panwar
    Sandeep Agarwal
    Shivanand Gamanagatti
    Ramesh Kumar
    Digestive Diseases and Sciences, 2023, 68 : 1016 - 1025
  • [6] Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease
    Anand, Abhinav
    Singh, Amit A.
    Elhence, Anshuman
    Vaishnav, Manas
    Biswas, Sagnik
    Gunjan, Deepak
    Gamanagatti, Shivanand R.
    Nayak, Baibaswata
    Kumar, Ramesh
    Shalimar
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (02) : 362 - 371
  • [7] What will happen in patients with advanced nonalcoholic fatty liver disease?
    Kimura, Takefumi
    Tanaka, Naoki
    Tanaka, Eiji
    HEPATOBILIARY SURGERY AND NUTRITION, 2019, 8 (03) : 283 - 285
  • [8] Nonalcoholic Fatty Liver Disease
    Wang, Xiao Jing
    Malhi, Harmeet
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (09) : ITC65 - ITC80
  • [9] Nonalcoholic Fatty Liver Disease
    Law, Kathryn
    Brunt, Elizabeth M.
    CLINICS IN LIVER DISEASE, 2010, 14 (04) : 591 - +
  • [10] Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
    Castera, Laurent
    Friedrich-Rust, Mireen
    Loomba, Rohit
    GASTROENTEROLOGY, 2019, 156 (05) : 1264 - +